Membership

Selcis BioPharma

Short Chain Fatty Acids (SCFA) are bacterial metabolites produced from fermentation products of dietary fibers and they are major mediators of differentiation, maturation, and activation of intestinal tissue and exerts potent effects on colonic mucosal functions through inhibition of inflammation.

An intestinal dysbiosis can be caused by antibiotics or poor diets, and can lead to decreased levels of SCFA´s in the gut. By improving the nutritional condition of the colon mucosa it may be possible to prevent or even alleviate some diseases. Of the biological active substances formed, the most important is butyric acid which stimulates mucosal cell proliferation, blood flow and oxygen uptake, resulting in a reduced gut permeability and influx of toxic/inflammatory substances to the circulation and may therefore decrease the risk for endotoxemia (low-grade inflammation) and associated diseases.

Selcis BioPharma is developing a technology where SCFA´s can be delivered to the colon and potentially prevent or restore gut homeostasis.

Cyxone AB

Cyxone AB (publ) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. For more information, please visit www.cyxone.com.

Hologic

Hologic is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

As a leader in women’s health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind. We provide laboratories of all sizes with world-leading technology for population-based screening for cervical cancer and breast cancer, rapid and accurate tests for sexually transmitted diseases, respiratory infections and much more. Since it was founded in 1985, Hologic has pushed the boundaries of diagnostics, surgery, and medical imaging several times.

Ergomed

Founded in 1997, Ergomed is a complete, global Phase I-IV clinical development and trial management service partner with leading expertise in developing rare diseases and oncology drugs. Pioneers in rare disease drug development since 1998, Ergomed embody a family & patient-centric approach to recruitment and retention with access to global patients in vital geographical areas. To further strengthen Ergomed CRO’s strong operational footprint, Ergomed invested in a strategic US acquisition of MedSource CRO, fully integrated in early 2021. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO).

Ergomed has supported and managed clinical development, trial management, pharmacovigilance, and medical information services for over 300 clients in more than 100 countries.

LifeSci Advisors

LifeSci Advisors provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. LifeSci Advisors increases client visibility within the investment community and educates investors on opportunities offered by these companies. Our core capabilities include institutional and high-net-worth investor access, non-deal roadshow planning and execution, corporate communications, KOL Events/R&D Days, and corporate advisory.

With a local presence in New York, Chicago, Boston, London, Paris, and Tel-Aviv, LifeSci Advisors provides high quality service for clients with our intensive healthcare sector specialization. The LifeSci team has 350+ years of healthcare experience in sell-side research, institutional equity sales, capital markets/investment banking, institutional investing, VC investing and strategic IR advisory. We have long-standing relationships with key investors and senior professionals across the industry. Our healthcare expertise allows us to provide objective, unbiased advice to private and public biotech, specialty pharma, medical technology, diagnostics, and healthcare services companies.

LifeSci Advisors employs a “client as partner” approach to our company relationships. From the beginning of each client relationship, we immerse ourselves in the subject matter and work closely with the client to develop an unparalleled and thorough understanding of the value of their business, the opportunities they’re addressing and their unique value proposition. With this insight, LifeSci Advisors provides each client with thoughtful and strategic recommendations related to corporate communications, investor targeting and investor outreach. These recommendations are specifically tailored to each client’s unique needs and designed to help them achieve their investor relations goals. We strive to effectively communicate each client’s investment thesis, which builds important momentum for the company’s investment story.

Poolia Life Science

Poolia Life Science is a preferred partner for large organisations, start up and scale up companies within Life Science. With our Quality Assured processes, we match high competence candidates with their next career opportunity.

We can help with consultants and/or permanent recruitments. We use our expertise and experience within Life Science recruitment to understand the industry’s and candidates’ behavioral patterns to find the specific qualified skills your organization needs. With the vision Worklife of tomorrow, we at Poolia Life Science are passionate about both customers and candidates. Examples of Life Science fields that we operate within: Biotechnology, Medical Device Technology, Pharma, Research and Development, RA/QC/QA, Engineering, Production, Management and Medicine.

For more information about Poolia Life Science please see: https://www.poolia.se/om-poolia/specialistomraden/life-science/

Apoglyx

Apoglyx exists to bring innovative therapies to patients. Our most advanced approach is targeting systemic inflammatory diseases like acute pancreatitis, COVID-19 and sepsis, where an overreaction of the immune system harms the body’s own organs. The company’s innovative molecules modulate cell transmembrane transport through aquaporin-9, a novel drug target. Aquaporins are channels for water to enter and leave cells, with broad importance in health and disease.

Estea

We create value for society and our investors by developing and investing in commercial real estate and social infrastructure. In Lund, in the middle of Medicon Valley, we are developing Forskaren, a hub for research and innovation.

Suvoda

Suvoda is an innovative SaaS company, focused on transforming clinical trials using the power of technology. Suvoda’s Interactive Response Technology (IRT) system solves complex patient randomization and clinical trial supply chain challenges, so that customers have peace of mind to focus on their patients. Suvoda IRT sets clinical trials up for success by offering a variety of configurable and customizable features, powerful reporting, and advanced functionality, built to support complex and innovative study designs. Suvoda has offices and staff around the world, offering exceptional customer and advisory services to biopharmaceutical companies and clinical research organizations of all sizes.

Bio T

BioT is an easy-to-integrate cloud-based Connected Care platform, designed to instantly connect between medical devices, patients and, caregivers to ensure a seamless continuum of care.

Our unique Triple C solution makes it possible to:

• CONNECT – Connect medical devices to the cloud easily and securely
• COLLABORATE – Engage with patients and caregivers directly and effectively
• CARE – Provide better care solutions by harnessing data and provide actionable insights

BioT’s connected care platform provides secure device connectivity, remote patient monitoring, and analysis, digital patient engagement, billing, and operations management.
In addition, BioT offers extension modules for improving patient adherence, increasing treatment efficacy, and preventing deterioration, with features like Patient-Reported Outcome (PROM) questionnaires, adherence prediction, and more.

By using BioT, you will significantly shorten time and cost to market, ensure regulatory compliance, minimize cybersecurity risks, and dramatically reduce your operational costs.